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Abstract
Introduction: Biomarkers that improve stratification of colorectal cancer patients for
adjuvant therapy versus resection alone, or that are predictive of response to
therapeutic agents, have the potential to greatly improve patient selection for such
therapies. The aim was to determine proteins differentially expressed within the
malignant epithelial glands and closely associated stromal elements compared to
matched normal mucosa, and to characterise the over-expression of one such
protein as a potential biomarker.
Methods: Protein from laser microdissected tumor and normal mucosa was analysed
by two dimensional difference gel electrophoresis (2D DIGE) and mass spectrometry
to determine differentially over expressed tumor proteins. Tumor over-expression of
one such protein, desmin, was quantified using immunofluorescence staining in a
larger cohort. Dual staining for desmin and vimentin, or desmin and von Willebrand
factor, was performed to determine the cell type of interest.
Results: Desmin expression was significantly increased between stage I and III
tumors, (P < 0.0001), and stage II and III tumors, (P < 0.0001). Strong focal desmin
expression was found in stroma directly adjacent to carcinomatous glands and
microvessels. These cells showed co-localisation of desmin and vimentin in close
association with cells expressing VWF, indicating they were pericytes. Significantly
higher levels of desmin-positive pericytes were observed in late stage tumors,
consistent with increased angiogenesis.
Conclusion: Pericyte coverage of vasculature is a marker of vessel maturation, hence
desmin expression may have use as a marker for microvessel maturation. Clinical
trials will be needed to determine its use in identifying tumors that will be less
responsive to anti-angiogenic therapy.
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The staging of colorectal cancer (CRC) could be improved as up to 25% of patients
deemed early stage (no regional lymph node or distant metastasis) relapse following
presumed curative surgery [1]. This is likely caused by circulating tumor cells [2,3]
or by established micro-metastatic disease in local lymph nodes or distant sites.
Identification of a biomarker for more advanced disease in the primary tumor may
result in down-staging the disease and thus identify a more appropriate selection of
patients for increased surveillance and adjuvant therapy. Targeted therapy, such as
anti-VEGF monoclonal antibody therapy, has shown a small but significant increase
in progression-free and overall survival in a proportion of metastatic CRC patients
in clinical trials [4], however many patients show resistance to anti-VEGF therapy.
The identification of predictive biomarkers would therefore significantly aid in
patient selection to improve efficacy and reduce the toxicity and cost of targeted
therapy.
The analysis of alterations in the tumor tissue microenvironment has the potential to
identify useful CRC biomarkers. Changes in the tumor microenvironment would influ-
ence the gene expression profile of surrounding epithelial and stromal cells [5]. Host
factors and signalling between the tumor cells and neighbouring stromal cells play a
role in angiogenesis, invasion and metastasis [5-7]. A change in the tumor microenvir-
onment can lead to changes in the molecular cross-talk between epithelial and stromal
cells (including endothelial cells), induced by heterotypic cell-to-cell contacts or signal-
ling molecules by paracrine or autocrine actions (reviewed in [8]). Such changes in
protein expression may provide useful biomarkers of tumor progression or as predic-
tive biomarkers for tumor resistance to targeted therapy.
As tumor tissue is heterogeneous and may contain lymphoid aggregates and
smooth muscle cells, it is important therefore to use laser micro-dissected (LMD)
colorectal tissues for differentially expressed tumor marker identification [9,10]. We
used laser microdissection (LMD) to collect areas of epithelium and closely asso-
ciated stromal elements from tumor and matched normal mucosal tissue. Two
dimensional difference gel electrophoresis (2D DIGE) was used to quantify the differ-
ence in the protein expression profiles of the samples to identify potential tumor
biomarkers. This system encompasses a novel fluorescence 2D gel technique
enabling multiplexing within the same gel, together with dedicated software for auto-
mated spot detection, background subtraction and quantitative spot volume calcula-
tions normalised to the internal reference sample. The software module matches
images from different gels to provide statistical data on differential protein abun-
dance. Multiplexing allows inclusion of a pooled reference sample, that is used for
normalisation within the gel and comparisons between gels, a distinct advantage
over conventional 2D electrophoresis.
The aims of this study were firstly to identify proteins differentially expressed in
malignant epithelium and closely associated stromal elements, compared to matched
normal mucosa using 2D DIGE and mass spectrometry (MS). Secondly, to analyse the
over-expression of one tumor protein in a larger cohort of CRC samples as a means to
validate the proteomic platform for differential protein identification, and thirdly, to
characterise the cell type of origin.
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Patient specimens
Samples of tumor and matched normal mucosa (taken from the furthest resection
margin) were collected from consecutive CRC patients undergoing resection surgery at
The Queen Elizabeth Hospital, and snap frozen in liquid nitrogen. Additional tumor
sections for immunostaining were obtained from archived formalin-fixed, paraffin-
embedded tumor blocks. Patients that had received neoadjuvant therapy were excluded
from the study. Ethics approval was received from the institutional Ethics of Human
Research Committee (protocol 1993/59) and informed consent was obtained in all
cases.
Laser microdissection (LMD) and protein preparation for 2D DIGE
LMD was performed on paired tumor-normal tissues from 4 stage III cases. Frozen tis-
sue embedded in OCT was cryo-sectioned (30 μm), placed on foil-framed PET mem-
brane slides (Leica, Wetzlar, Germany), stored at -80°C, and thawed just prior to use.
Sections for LMD were unfixed and unstained while adjacent sections were fixed and
stained with haematoxylin for confirmation of morphology by a histopathologist. Using
the Leica AS LMD system (Leica, Wetzlar, Germany), tissue was microdissected and
collected in the cap of a 0.5 ml microfuge tube containing 40 μlo fs a m p l eb u f f e r( 3 0
mM Tris, 7 M Urea, 2 M Thiourea, 4% (w/v) CHAPS). Areas of tumor which included
neoplastic glands and adjacent stroma were selected for LMD, excluding extramural
tumor extension to avoid capturing cells of the muscularis propria. After solubilisation
overnight, samples were purified using a 2D Clean Up kit (Bio-Rad, Hercules, CA,
USA), resuspended in an appropriate volume of sample buffer, and quantified using
the EZQ Protein Quantification Kit (Invitrogen, Carlsbad, CA, USA).
Scarce Labelling 2D DIGE
Five μg of each protein sample was diluted to 1 μg/μl in DIGE labelling buffer, pH 8.5,
reduced with 1 μl of 2 mM TCEP (Sigma, St Louis, MO, USA), and labelled with 2 μl
of 2 nmol Cy5 dye according to the manufacturer’s protocol (GE Healthcare, Buckin-
ghamshire, UK). Similarly, 5 μg of a pooled internal control (consisting of equal
amounts of protein from all samples in the cohort) was labelled with Cy3, mixed with
each of the individual tumor and normal samples and diluted in rehydration buffer (7
M Urea, 2 M Thiourea, 4% CHAPS, 1% IPG Buffer, 13 mM DTT) to a final volume of
450 μl. Samples were rehydrated overnight into 24 cm pH 3-7 non-linear IPG strips
(GE Healthcare) at 50 V, followed by isoelectric focusing for approximately 70,000
Vhrs. Second dimension SDS PAGE was carried out at 350 V on 8-15% gradient polya-
crylamide gels. Imaging of Cy3 and Cy5 labelled protein spots was performed using a
Typhoon Imager 9400 (GE Healthcare). The matched tumor-normal gel images were
cropped with ImageQuant v3 software (GE Healthcare) and loaded into the DeCyder™
v5 Batch Processor software. The software was set to calculate the average abundance
change ratio of proteins across the 8 gels and the significance of the change using Stu-
dent’s paired t-test. The gels were analysed using the Biological Variation Analysis
module of the DeCyder™ v5 software. For identification by tandem MS (MS/MS), pro-
tein spots were excised from a preparative gel containing 250 μgp r o t e i nt h a th a d
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ver stain [11].
Protein Identification
Protein spots excised from the preparative gel were washed 3 times with 25 mM
ammonium bicarbonate/50% acetonitrile (ACN), dehydrated with ACN, and digested
overnight at 37°C in 20 μlo f2 0μg/ml trypsin in 25 mM ammonium bicarbonate/10%
ACN. MS/MS was performed on a HTC ultra 3D Ion Trap (Bruker Daltonic GmbH,
Bremen, Germany) fitted with a 0.075 × 150 mm C18 column (Zorbax 300 SB-C18,
3.5 μm, Agilent Technologies, Santa Clara, USA). Peak lists were generated using Data
Analysis V 2.4 (Bruker Daltonik GmbH). The MSDB 20060831 database was searched
using the MASCOT search engine, under the parameters of fixed carbamidomethyla-
tion of cysteines, variable oxidation of methionines, MS/MS and mass tolerance of 0.4
Da, and one missed trypsin cleavage.
Immunofluorescence Staining
Verification of tumor over-expression of one protein (desmin) identified from the 2D
DIGE study was performed using immunofluorescence (IF) on 36 tumor and matched
normal mucosal tissues from 15 stage I, 11 stage II, and 10 stage III cases. Frozen
tumor tissue was embedded in OCT and serial 7 μm cryo-sections were cut and placed
on HistoGrip™ (Invitrogen, Carlsbad, CA, USA) coated slides. Western blotting was
performed to assess the specificity of the anti-desmin mouse IgG1 monoclonal anti-
body (ab6322 Abcam, Cambridge, MA, USA) for use in IF. Fifty μg tumor protein was
separated by 1 D PAGE, immunoblotted with the desmin antibody and detected using
a fluorescent Cy3-conjugated secondary antibody (GE Healthcare). Sections for IF were
fixed in ice cold acetone for 5 min, followed by washing in PBS. One section of each
tumor was stained with Diff Quik (Invitrogen) for histological reference. Sections were
blocked for the non-specific binding of both primary and secondary antibodies by
incubation with Image-It™ Signal Enhancer (Invitrogen) for 30 minutes, followed by
incubation with 10% goat serum (GS) in PBS for 30 minutes. Sections were washed
thoroughly with PBS and treated with a 1:30 dilution of the anti-desmin mouse anti-
body in 10% GS/PBS at 4°C overnight in a humidity box. Bound antibody was detected
with Alexa 488 conjugated anti-mouse (Invitrogen) diluted 1:500 in 10% GS/PBS for 1
hour at room temperature in a humidity box in the dark. As negative controls, sections
were treated with 10% GS/PBS only or with a 1:20 dilution of an IgG1 isotype control
antibody. All sections were counter stained with DAPI at 0.5 μg/ml (Sigma, St Louis,
MO, USA) in the dark for 30 minutes, air dried, and mounted with ProLong
® Gold
anti-fade reagent (Invitrogen).
Co-localisation of desmin and vimentin was assessed using a subset of 17 tumor tis-
sues (8 stage I, 6 stage II and 3 stage III) chosen randomly from the cohort. Sections
were treated as previously described with a1 : 3 0d i l u t i o no fd e s m i na n t i b o d yp l u sa
1:20 dilution of vimentin rabbit antibody (ab16700, Abcam). Bound antibodies were
detected by Alexa 488 conjugated anti-mouse antibody (Invitrogen) diluted 1:500 and a
Cy5 conjugated anti-rabbit antibody (GE Healthcare) diluted 1:200.
To determine desmin and VWF staining, 5 μm sections from formalin fixed paraffin
embedded stage III tumors (n = 5) were placed on HistoGrip™ (Invitrogen) coated
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by washes in 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and deionised
water. Slides were incubated at 37°C for 15 min in 0.05% trypsin/0.1% calcium chlor-
ide, pH 7.8 in a humidity chamber. Slides were thoroughly washed with deionised
water, followed by PBS, blocked in 1% BSA/0.3% Tween-20 in PBS for 1 hour at room
temperature in a humidity chamber, and incubated with a 1:30 dilution of desmin
mouse antibody (ab6322, Abcam) and a 1:800 dilution of VWF rabbit antibody
(ab6994, Abcam) at 4°C overnight in a humidity box. Slides were washed three times
in PBS, incubated with anti-mouse-Alexa 488 diluted 1: 500 and anti-rabbit Alexa 568
(both from Invitrogen) diluted 1: 500 for 1 hour at room temperature in the dark. As
negative controls, sections were treated with 1% BSA/0.3% Tween-20 in PBS only or
with a 1: 20 dilution of IgG isotype control antibody. All sections were counter stained
with DAPI at 0.5 μg/ml (Sigma) in the dark for 30 min, air dried, and mounted with
ProLong
® Gold anti-fade reagent (Invitrogen).
Immunofluorescence Analysis
Desmin staining was evaluated by imaging the entire area of each section at 10 × mag-
nification in monochrome using an Olympus BX51 fluorescence microscope. Images
were taken using 460-495 nm, 330-385 nm, 590 nm and 663 nm long pass filters to
capture the Alexa 488, DAPI, Alexa 568, and Cy5 images respectively. Colour was
added and images overlayed. Desmin staining was quantified using the AnalySIS LS
Research phase analysis tool (Soft Imaging Systems, Olympus, Münster, Germany)
which gave the area (μm
2) and % area of the total image that was positive for desmin.
This process was repeated to quantify the level of DAPI staining. Prior to phase analy-
sis, the pixel threshold of each image was adjusted to only include areas of positive
fluorescence, excluding background. The final percentage area positive for desmin
staining was then calculated against the total cell area, as determined by the quantified
level of DAPI staining. For each tumor the % area of desmin staining across the tissue
section was averaged. As desmin is a smooth-muscle cell marker, areas of muscularis
mucosa were excluded from analysis.
Statistical Analysis
Student’s paired t-test was used to assess differences in protein expression between
tumor and normal LMD samples (DeCyder™ software, GE Healthcare) and to assess
the difference in desmin expression among stage I, II and III tumors (Graph Pad Prism
5.0). A P value of < 0.05 was accepted as significant.
Results
2D DIGE and protein identification
The average total protein yield of the tumor and normal samples following LMD was
41.5 μg (range 16.8-66.2) and 51.0 μg (range 19.4-82.6), from average areas of 28 mm
2
and 24 mm
2 respectively. An example of LMD is shown in Figure 1A. The 2D DIGE
analysis showed 4 spots significantly higher in abundance across the 4 tumor samples
(Figure 1B and Table 1). These proteins spots were identified by tandem MS (Table 1).
Desmin (spot 1 Figure 1B) was identified with the highest Mowse score, the highest
number of matched peptides and the largest sequence coverage and was selected for
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measured across the 8 gels is shown by graphical view (DeCyder™ software) in Addi-
tional file 1.
Quantification of desmin expression
The origin and extent of the desmin expression was evaluated by immunofluorescence
(IF) on tissue from stage I, II and III tumors. The desmin antibody showed a single
band at the expected MW on Western blotting (Additional file 2). Desmin was
expressed in the stromal cell area closely associated with the malignant epithelial
glands of the tumor tissue (Figure 2). The desmin stained cells appeared in close asso-
ciation with malignant crypts. Low levels of stromal desmin staining were observed in
the normal tissues, and this was generally sparse and discontinuous. The mean percen-
tage areas of positive desmin staining (within the epithelial and stromal cell areas,
excluding muscularis mucosa) for 15 stage I, 11 stage II and 9 stage III tumors are
shown in Figure 3. Stromal desmin expression was significantly higher in stage III
 
 
 
1 
2 
3 
4 
B 
A 
Figure 1 Scarce labelling 2D DIGE on protein from laser microdissected tissue. A, fixed and stained
tumor tissue section (LHS), arrow points to malignant epithelial glands, unfixed and unstained section prior
to LMD (centre), and after LMD (RHS). B, a scanned gel image of Cy5-labelled tumor protein with the
circled proteins identified as significantly over-expressed in tumor versus matched normal mucosa across
the 4 pairs (DeCyder™). Spot 1, identified by MS/MS as desmin shows an apparent molecular weight (MW)
of 53 kDa, and isoelectric point (pI) of 5.21.
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There was no significant difference in the level of stromal desmin expression between
stage I and II tumors (Student’s t-test). While there was a significant correlation
between the presence of a desmoplastic reaction and late tumor stage (P = 0.04, Fish-
er’s exact test), no correlation was shown between desmoplastic reaction and high ver-
sus low level of desmin staining.
Desmin, vimentin and VWF co-localisation studies
Desmin and vimentin double immunostaining was performed on 17 tumor samples to
assess co-localisation. Desmin and vimentin co-localised in cells amongst the malignant
crypts, in particular surrounding blood vessels (Figure 4). In addition there was strong
vimentin staining of stromal cells amongst the malignant crypts as well as occasional
stromal cells staining for desmin only. Desmin and VWF double staining commonly
Table 1 Proteins higher in abundance in tumour relative to matched normal mucosa
2D DIGE DeCyder™ calculations Mass spectrometry
Spot
number
Protein
identified
Patient T-N spot
volume ratio
Ave.
Ratio
P
value
Score Peptides
Matched
% seq.
MS/MS
1 Desmin 1 2.79 2.25 0.02 500
b 11 31
P17661
a 2 1.19
3 1.58
4 3.45
2 HSP60 1 3.51 2.57 0.01 12.4
c 71 0
P10809 2 1.46
3 1.91
4 3.10
3 14-3-3 b 1 1.48 2.0 0.01 234
b 62 8
P31946 2 1.57
3 1.65
4 3.46
4 b Tubulin 1 1.59 2.98 0.017 117
b 25
P07437 2 3.01
3 3.55
4 2.42
a, UniProtKB database accession number; b, Probability-based Mowse score (Mascot search engine at Matrixscience.
com); c, Protein Lynx score (Protein Lynx Global server) - an algorithm based measure of confidence of protein identity;
d, Percentage sequence coverage for MS/MS identification.
ab c
Figure 2 Desmin immunofluorescence staining. Representative examples of desmin staining with Alexa
488 (green) conjugated secondary antibody, and DAPI nuclei stain (blue) performed on colon tissues. A,
tumor section showing stromal desmin staining. B, enlargement of white boxed area in A showing desmin
positive cells surrounding a crypt. C, from the matched normal tissue section showing desmin-positive
muscularis mucosa across the top of the section. Note the much reduced desmin expression in the normal
epithelial tissue. Scale bar = 100 μm.
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normal mucosa from some stage III and IV tumors, but not from early stage tumors.
Discussion
Proteomic determination of factors expressed by tumor cells and host stromal cells,
either inherently or as a result of tumor-host interactions, has been shown to be useful
in elucidating molecular pathways of tumor growth, invasion and metastasis (reviewed
in [8]). In our 2D DIGE study, desmin was found over-expressed in colorectal tumors
relative to matched normal mucosa. Previous reports of proteomic studies of differen-
tial expression of this protein in colorectal tumor tissues have shown conflicting
results, from desmin over-expression [12], in agreement with our study, to reduced
expression [13]. In other proteomic studies desmin was not identified among proteins
over-expressed in colorectal tumors [14,15]. The varying results could be due to the
fact that these studies were performed on tissue that had not been laser microdis-
sected: the strong desmin expression by smooth muscle cells of the muscularis muco-
sae and muscularis propria would mask any differences between tumor and normal
epithelium.
Desmin is a smooth-muscle type intermediate filament protein, expressed by smooth
muscle cells, but also found expressed in fibrotic tissue in wound healing and in tumor
‘desmoplastic’ stroma, yet the origin of the cell type expressing desmin has been
   Tumor stage 
Figure 3 Scatter plot of % area of desmin staining according to tumor stage. Areas of muscularis
mucosa and vasculature were excluded from analysis. Levels of staining were significantly increased
between early stage (stage I and II) and stage III tumors, * P < 0.0001.
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have been described variously as peritumoral fibroblasts, reactive (desmoplastic)
stroma, cancer- or tumor-associated fibroblasts (CAF/TAF), and myofibroblasts. These
cells belong to a functionally heterogeneous cell population and despite similar mor-
phology, display distinct phenotypes in different pathological settings [16-19]. Myofi-
broblasts within the tumor stroma are thought to transdifferentiate from quiescent
fibroblasts, driven by tumor-derived cytokines, in particular transforming growth factor
(TGF)b [5]. Tumor stromal myofibroblasts have been shown to play a pivotal role in
the switch from non-invasive to invasive cancer [16,18] and to promote and sustain
tumor vasculature [20]. Using double-immunostaining we found different populations
of cells within the tumor stroma i.e. vimentin-positive cells, as well as cells positive for
both vimentin and desmin and some cells staining positive for desmin only (Figure 4).
Previously, several myofibroblast subpopulations have been described based on their
different expression of the intermediate filaments vimentin and desmin, with and with-
out a-smooth muscle actin (a-SMA) [16,17,21]. These subpopulations have not been
fully characterised but may reflect the continuum of differentiation from quiescent
fibroblast (vimentin-positive, a-SMA negative, desmin negative) to myofibroblast (a-
SMA positive, vimentin and/or desmin positive).
Figure 4 Desmin and vimentin co-localisation. Dual immunostaining staining performed on stage III
tumor using Alexa 488 (green)- and Cy5 (red)- conjugated secondary antibodies for desmin and vimentin
respectively, counterstained with DAPI (blue). Co-expression of desmin and vimentin by the same cell
results in overlapping of the fluors, and appears yellow. Scale bar = 100 μm. Large amounts of vimentin
staining appear between the epithelial crypts given vimentin is a fibroblast/mesenchymal marker and will
stain stromal cells, endothelial cells and pericytes. The co-staining pattern of desmin and vimentin appears
to be in cross and vertical sections of microvessels. Red arrows indicate areas of tissue stroma, white
arrows malignant epithelial glands and yellow arrows cross-sectioned blood vessels showing co-localisation
of desmin and vimentin.
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blood vessels from the earliest stages of capillary sprouting and throughout angiogen-
esis [22,23]. Such cells have also been described as mural cells [24] or highly motile
myofibroblast-like cells [25]. As a result of angiogenic signals, pericytes are recruited to
developing endothelial tubes and express desmin in increasing amounts as they mature
and elongate to form a stable sheath around the newly formed vessels [26,27]. The
mature pericytes become focally embedded within the basement membrane adjacent to
the endothelial cells [26,28] and are considered to be essential to angiogenesis both in
normal physiology and in cancer [29,30].
Figure 5 Desmin and von Willebrand factor (VWF) immunostaining. Dual immunostaining performed
on stage III tumor tissue. Desmin was visualised with an Alexa 488 (green) conjugated secondary and VWF
with an Alexa 568 (red) conjugated secondary, counterstained with DAPI (blue), scale bar = 100 μm. Co-
localisation of the proteins appears yellow. Red arrows indicate cells positive for VWF, white arrows cells
positive for desmin and yellow arrows co-localisation for desmin and VWF. The tumor section shows a
blood vessel outlined by cells showing co-localisation of desmin (pericytes) and VWF (endothelial cells) in
juxtaposition.
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vessels in our study suggested the presence of pericytes (desmin-positive, vimentin-
positive) tightly associated with the endothelial cells (also vimentin-positive) of micro-
vessels (Figure 4). Double staining for desmin and the endothelial cell marker VWF
[31] supports this conclusion (Figure 5). Pericytes and vascular smooth muscle cells
(VSMC) comprise the mural cells that coat blood vessels, and it is now recognised that
there is a continuum of phenotype from VSMC surrounding larger vessels to the typi-
cal pericytes coating capillaries and venules (reviewed in [29]). We therefore concluded
that the desmin-positive, vimentin-positive cells were typical pericytes, rather than
VSMC, coating the tumor micro-vessels. Taken together, our results show that the
desmin expression is derived from both stromal myofibroblasts surrounding malignant
crypts and from pericytes found in close contact with the tumor microvessels.
In our study there was a significantly higher level of desmin expression in stage III
tumors when compared to both stage I and II tumors, suggesting a higher level of
mature microvasculature in the late stage tumor tissue or a higher level of desmoplasia
(or both). However there was no significant correlation between the level of desmin
staining and the presence of desmoplasia in the tumors. This may be due to the fact
that colon tumors with high desmoplastic grade have been shown to have a reduced
number of microvessels (compared to tumors with low grade desmoplasia), but those
vessels were mature with a higher level of pericyte coverage [32]. This would tend to
balance out levels of desmin expression between tumors with high or low grade of des-
moplasia, as we have found.
Mature pericyte-coated vessels are quiescent, and not dependent on angiogenic
factors for survival [33,34], whereas uncoated vessels are considered to be unstable
or immature, and responsive to angiogenic signals [35,36]. A significant proportion
of metastatic CRC patients treated with anti-VEGF monoclonal antibody therapy or
the tyrosine kinase inhibitors Sunitinib and Vatalanib, have shown poor response
rates and generally only a modest effect on survival rates when used with standard
chemotherapy [37]. Poor outcomes of these drug trials may be due to the presence
of mature vasculature within the targeted tumors conferring a resistant phenotype
[33,35,38-40].
In conclusion, desmin staining, identifying pericyte coverage and extent of mature
tumor vasculature, may thus be worthy of further investigation as a biomarker to pre-
dict the efficacy of anti-angiogenic cancer therapy. Qualification of its use as a predic-
tive biomarker will depend on a clinical trial incorporating desmin immunostaining of
tumors from patients treated with or without anti-VEGF therapy.
Additional material
Additional file 1: Graphical view of 2D DIGE protein spot abundance generated by DeCyder™™ software.
The standardised log abundance of desmin is displayed on the Y-axis, with the normal (Group 1) and tumor
(Group 2) samples displayed on the X-axis. The line represents the average increase in log abundance.
Additional file 2: Confirmation of the specificity and integrity of the desmin antibody by western blotting.
Fifty micrograms of whole tumour protein was separated by PAGE, immunoblotted with the desmin antibody
ab6322 (Abcam) and detected using a fluorescent Cy3-conjugated secondary antibody. A single band slightly
below 50 kDa was observed. The molecular weight markers were ‘Dual Color’ prestained SDS-PAGE standards (Bio-
rad).
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Acknowledgements
We thank the Cancer Council of South Australia for grant support (grant number 508025), Professor Peter Hewett for
facilitating the collection of samples from patients during surgery, and John Terlet and staff at Adelaide Microscopy
for assistance with immunostaining quantification software.
Author details
1Department of Haematology-Oncology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia.
2Department of
Physiology, University of Adelaide, SA 5005, Australia.
3Department of Physiology, Flinders University, Bedford Park, SA
5042, Australia.
4Department of Medicine, University of Adelaide, SA 5005, Australia.
5Department of Gastroenterology
and Hepatology, The Queen Elizabeth Hospital, Woodville, SA 5001, Australia.
Authors’ contributions
GA carried out the proteomic studies, IF staining and quantification, statistical analyses and participated in drafting the
manuscript. TC contributed to the interpretation of proteomic studies and mass spectrometry and reviewed the
manuscript. TP contributed to drafting the manuscript and critical review. ZI and GH performed IF staining. AC
advised on the methodology and interpretation of IF quantification and critically reviewed the manuscript. JH
conceived the study, contributed to its design and coordination, participated in drafting the manuscript and critical
review. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 November 2011 Accepted: 5 December 2011 Published: 5 December 2011
References
1. O’Connell JB, Maggard MA, Ko CY: Colon Cancer Survival Rates With the New American Joint Committee on Cancer
Sixth Edition Staging. J Natl Cancer Inst 2004, 96:1420-1425.
2. Tsavellas G, Patel H, Allen-Mersh TG: Detection and clinical significance of occult tumour cells in colorectal cancer.
Br J Surg 2001, 88:1307-1320.
3. Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE: Identification of early-stage colorectal
cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal
lavage fluid for malignant cells. Clin Cancer Res 2006, 12:417-423.
4. Hsu JY, Wakelee HA: Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs 2009,
23:289-304.
5. De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
6. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF: Vascular stroma
formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999,
5:1041-1056.
7. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor
progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
8. Karagiannis GS, Pavlou MP, Diamandis EP: Cancer secretomics reveal pathophysiological pathways in cancer
molecular oncology. Mol Oncol 2010, 4:496-510.
9. Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, Sugiyama K, Evers BM: Analysis of differential gene expression
patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 2005, 128:480-486.
10. Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI: Application of laser capture microdissection and
proteomics in colon cancer. Mol Pathol 2001, 54:253-258.
11. Jin LT, Hwang SY, Yoo GS, Choi JK: A mass spectrometry compatible silver staining method for protein
incorporating a new silver sensitizer in sodium dodecyl sulfate-polyacrylamide electrophoresis gels. Proteomics
2006, 6:2334-2337.
12. Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, Shen T, Zhou Y, Chen H, Chu Z, et al: Proteomics Identification of
Desmin as a Potential Oncofetal Diagnostic and Prognostic Biomarker in Colorectal Cancer. Mol Cell Proteomics
2009, 8:1878-1890.
13. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM: Proteome analysis of human colon
cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4:793-811.
14. Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI: Proteomic expression analysis of colorectal
cancer by two-dimensional differential gel electrophoresis. Proteomics 2005, 5:2602-2611.
15. Álvarez-Chaver P, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Martínez-Zorzano VS, Páez de la Cadena M:
Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int J Biochem Cell Biol 2007,
39:529-540.
16. De Wever O, Demetter P, Mareel M, Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J
Cancer 2008, 123:2229-2238.
17. Kunz-Schughart LA, Knuechel R: Tumor-associated fibroblasts (part I): Active stromal participants in tumor
development and progression? Histol Histopathol 2002, 17:599-621.
18. Franco OE, Shaw AK, Strand DW, Hayward SW: Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev
Biol 2010, 21:33-39.
19. Richman PI, Tilly R, Jass JR, Bodmer WF: Colonic pericrypt sheath cells: characterisation of cell type with new
monoclonal antibody. J Clin Pathol 1987, 40:593-600.
Arentz et al. Clinical Proteomics 2011, 8:16
http://www.clinicalproteomicsjournal.com/content/8/1/16
Page 12 of 1320. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR: Stromal Cells Promote Angiogenesis and Growth of
Human Prostate Tumors in a Differential Reactive Stroma (DRS) Xenograft Model. Cancer Res 2002, 62:3298-3307.
21. Schmitt-Graff A, Desmouliere A, Gabbiani G: Heterogeneity of myofibroblast phenotypic features: an example of
fibroblastic cell plasticity. Virchows Arch 1994, 425:3-24.
22. Nehls V, Denzer K, Drenckhahn D: Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue
Res 1992, 270:469-474.
23. Verhoeven D, Buyssens N: Desmin-positive stellate cells associated with angiogenesis in a tumour and non-tumour
system. Virchows Arch B Cell Pathol Incl Mol Pathol 1988, 54:263-272.
24. Sims DE: The pericyte–A review. Tissue & Cell 1986, 18:153-174.
25. Kang N, Yaqoob U, Geng Z, Bloch K, Liu C, Gomez T, Billadeau D, Shah V: Focal adhesion assembly in myofibroblasts
fosters a microenvironment that promotes tumor growth. Am J Pathol 2010, 177:1888-1900.
26. Brey EM, McIntire LV, Johnston CM, Reece GP, Patrick CW Jr: Three-dimensional, quantitative analysis of desmin and
smooth muscle alpha actin expression during angiogenesis. Ann Biomed Eng 2004, 32:1100-1107.
27. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G: PDGFR[beta]+ perivascular progenitor cells in tumours regulate
pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7:870-879.
28. Armulik A, Abramsson A, Betsholtz C: Endothelial/pericyte interactions. Circ Res 2005, 97:512-523.
29. Raza A, Franklin MJ, Dudek AZ: Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J
Hematol 2010, 85:593-598.
30. Gerhardt H, Betsholtz C: Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003, 314:15-23.
31. Middleton J, Americh L, Gayon R, Julien D, Mansat M, Mansat P, Anract P, Cantagrel A, Cattan P, Reimund JM, et al: A
comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy
antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol 2005,
206:260-268.
32. Schmid SA, Dietrich A, Schulte S, Gaumann A, Kunz-Schughart LA: Fibroblastic reaction and vascular maturation in
human colon cancers. Int J Radiation Biol 2009, 85:1013-1025.
33. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established
human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
34. Abramsson A, Berlin O, Papayan H, Paulin D, Shani M, Betsholtz C: Analysis of mural cell recruitment to tumor
vessels. Circulation 2002, 105:112-117.
35. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM: Tumor vessel development and maturation
impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003, 162:183-193.
36. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.
Nat Med 2001, 7:987-989.
37. Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz H-J: Targeting metastatic colorectal cancer in 2008: a long way
from 5-FU. (Special Issue on Targeted Therapy)(fluorouracil). Oncology 2008, 22:456-462.
38. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C: Identification of a subset of
pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007,
121:2606-2614.
39. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM: Induction of
VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. Faseb J 2001,
15:1239-1241.
40. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Schadendorf D: Resistance to
antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant
melanoma. J Exp Med 2010, 207:491-503.
doi:10.1186/1559-0275-8-16
Cite this article as: Arentz et al.: Desmin expression in colorectal cancer stroma correlates with advanced stage
disease and marks angiogenic microvessels. Clinical Proteomics 2011 8:16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Arentz et al. Clinical Proteomics 2011, 8:16
http://www.clinicalproteomicsjournal.com/content/8/1/16
Page 13 of 13